The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 05, 2020

Filed:

Oct. 26, 2018
Applicant:

Massachusetts Eye and Ear Infirmary, Boston, MA (US);

Inventors:

Demetrios G. Vavvas, Boston, MA (US);

Georgios Trichonas, Boston, MA (US);

Joan W. Miller, Winchester, MA (US);

Yusuke Murakami, Newton, MA (US);

Assignee:
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/40 (2006.01); A61K 31/4178 (2006.01); A61K 38/00 (2006.01); A61K 38/05 (2006.01); A61K 38/55 (2006.01); A61K 31/12 (2006.01); A61K 31/195 (2006.01); A61K 31/4155 (2006.01); A61K 31/416 (2006.01); A61K 31/4174 (2006.01); A61K 31/519 (2006.01); A61K 45/06 (2006.01); A61K 9/00 (2006.01); A61K 38/06 (2006.01); A61B 3/028 (2006.01); A61B 5/00 (2006.01); A61F 9/00 (2006.01);
U.S. Cl.
CPC ...
A61K 38/05 (2013.01); A61B 3/028 (2013.01); A61B 5/4839 (2013.01); A61F 9/0008 (2013.01); A61K 9/0048 (2013.01); A61K 31/12 (2013.01); A61K 31/195 (2013.01); A61K 31/40 (2013.01); A61K 31/416 (2013.01); A61K 31/4155 (2013.01); A61K 31/4174 (2013.01); A61K 31/4178 (2013.01); A61K 31/519 (2013.01); A61K 38/005 (2013.01); A61K 38/06 (2013.01); A61K 45/06 (2013.01);
Abstract

Provided are methods and compositions for maintaining the viability of photoreceptor cells and/or retinal pigment epithelial cells in a subject with an ocular disorder including, for example, age-related macular degeneration (AMD) (e.g., dry or neovascular AMD), retinitis pigmentosa (RP), or a retinal detachment. The viability of the photoreceptor cells and/or the retinal pigment epithelial cells can be preserved by administering a necrosis inhibitor either alone or in combination with an apoptosis inhibitor to a subject having an eye with the ocular condition. The compositions, when administered, maintain the viability of the cells, thereby minimizing the loss of vision or visual function associated with the ocular disorder.


Find Patent Forward Citations

Loading…